Niche-to-niche migration of bone-marrow-derived cells

Trends in Molecular Medicine

Volumn 13, Issue 2, 2007, Pages 72-81

  Kaplan, Rosandra N ^a   Psaila, Bethan ^a   Lyden, David ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SENSING RECEPTOR; CATHEPSIN K; GELATINASE B; OSTEOPONTIN; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN RECEPTOR 1; VERY LATE ACTIVATION ANTIGEN 4;

BONE MARROW CELL; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELLULAR DISTRIBUTION; CLUSTER ANALYSIS; CONTROLLED STUDY; FETUS DEVELOPMENT; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIA; METASTASIS; MICROENVIRONMENT; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOBLAST; REVIEW; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE SPECIFICITY; TUMOR GROWTH;

ANIMALS; BLOOD VESSELS; BONE MARROW CELLS; CELL ADHESION; CELL MOVEMENT; CHEMOKINES, CXC; FETAL DEVELOPMENT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OSTEOBLASTS; RECEPTORS, CALCIUM-SENSING; SIGNAL TRANSDUCTION; TUMOR STEM CELLS;

EID: 33846798072     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.12.003     Document Type: Review

References (101)

1. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4 (1978) 7-25
2. Adams G.B., and Scadden D.T. The hematopoietic stem cell in its place. Nat. Immunol. 7 (2006) 333-337
3. Palis J., et al. Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. Development 126 (1999) 5073-5084
4. Cumano A., et al. Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, provide long-term multilineage reconstitution. Immunity 15 (2001) 477-485
5. de Bruijn M.F., et al. Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. EMBO J. 19 (2000) 2465-2474
6. Medvinsky A.L., and Dzierzak E.A. Development of the definitive hematopoietic hierarchy in the mouse. Dev. Comp. Immunol. 22 (1998) 289-301
7. Bollerot K., et al. The embryonic origins of hematopoietic stem cells: a tale of hemangioblast and hemogenic endothelium. APMIS 113 (2005) 790-803
8. Huber T.L., et al. Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature 432 (2004) 625-630
9. Mendes S.C., et al. Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. Development 132 (2005) 1127-1136
10. Takahashi T., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5 (1999) 434-438
11. Isner J.M., et al. Bone marrow as a source of endothelial cells for natural and iatrogenic vascular repair. Ann. N. Y. Acad. Sci. 953 (2001) 75-84
12. LaRue A.C., et al. Circulating blood island-derived cells contribute to vasculogenesis in the embryo proper. Dev. Biol. 262 (2003) 162-172
13. Pardanaud L., and Eichmann A. Identification, emergence and mobilization of circulating endothelial cells or progenitors in the embryo. Development 133 (2006) 2527-2537
14. Kiel M.J., et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121 (2005) 1109-1121
15. Lord B.I., et al. The relative spatial distributions of CFUs and CFUc in the normal mouse femur. Blood 46 (1975) 65-72
16. Nilsson S.K., et al. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood 97 (2001) 2293-2299
17. Wilson A., and Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 6 (2006) 93-106
18. Taichman R.S., and Emerson S.G. The role of osteoblasts in the hematopoietic microenvironment. Stem Cells 16 (1998) 7-15
19. Balduino A., et al. Bone marrow subendosteal microenvironment harbours functionally distinct haemosupportive stromal cell populations. Cell Tissue Res. 319 (2005) 255-266
20. Visnjic D., et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 103 (2004) 3258-3264
21. Calvi L.M., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 (2003) 841-846
22. Stier S., et al. Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood 99 (2002) 2369-2378
23. Nilsson S.K., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106 (2005) 1232-1239
24. Stier S., et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J. Exp. Med. 201 (2005) 1781-1791
25. Li W., et al. Primary endothelial cells isolated from the yolk sac and para-aortic splanchnopleura support the expansion of adult marrow stem cells in vitro. Blood 102 (2003) 4345-4353
26. Kopp H.G., et al. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20 (2005) 349-356
27. Avecilla S.T., et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat. Med. 10 (2004) 64-71
28. Nervi B., et al. Cytokines and hematopoietic stem cell mobilization. J. Cell. Biochem. 99 (2006) 690-705
29. Pilarski L.M., et al. Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood 93 (1999) 2918-2927
30. Yin T., and Li L. The stem cell niches in bone. J. Clin. Invest. 116 (2006) 1195-1201
31. Heissig B., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 (2002) 625-637
32. Kopp H.G., et al. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 13 (2006) 175-181
33. Kollet O., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12 (2006) 657-664
34. Petit I., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 3 (2002) 687-694
35. Peled A., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283 (1999) 845-848
36. Nagasawa T., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996) 635-638
37. Ara T., et al. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 19 (2003) 257-267
38. Dar A., et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat. Immunol. 6 (2005) 1038-1046
39. Adams G.B., et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439 (2006) 599-603
40. Wright D.E., et al. Physiological migration of hematopoietic stem and progenitor cells. Science 294 (2001) 1933-1936
41. Abkowitz J.L., et al. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 102 (2003) 1249-1253
42. de Sousa M. Cell traffic. In: Cuatrecasas P. (Ed). Receptors and Recognition (1976), Chapman & Hall 105-152
43. Kaplan R.N., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
44. Grunewald M., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
45. Massberg S., et al. Platelets secrete stromal cell-derived factor 1a and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J. Exp. Med. 203 (2006) 1211-1233
46. + hemangiocytes. Nat. Med. 12 (2006) 557-566
47. Orimo A., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005) 335-348
48. Salven P., et al. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 101 (2003) 168-172
49. Ceradini D.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004) 858-864
50. Okuyama H., et al. Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. J. Biol. Chem. 281 (2006) 15554-15563
51. Pola R., et al. Postnatal recapitulation of embryonic hedgehog pathway in response to skeletal muscle ischemia. Circulation 108 (2003) 479-485
52. Li B., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 20 (2006) 1495-1497
53. Lyden D., et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401 (1999) 670-677
54. Lyden D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
55. Studeny M., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 96 (2004) 1593-1603
56. Papayannopoulou T., et al. Molecular pathways in bone marrow homing: dominant role of a4b1 over b2-integrins and selectins. Blood 98 (2001) 2403-2411
57. Jin H., et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J. Clin. Invest. 116 (2006) 652-662
58. Peters B.A., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11 (2005) 261-262
59. Ruzinova M.B., et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone marrow-derived endothelial cells in spontaneous murine tumours. Cancer Cell 4 (2003) 277-289
60. Scadden D.T. The stem-cell niche as an entity of action. Nature 441 (2006) 1075-1079
61. Li L., and Neaves W.B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66 (2006) 4553-4557
62. Rafii S., and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9 (2003) 702-712
63. Laflamme M., and Murry C.E. Regenerating the heart. Nat. Biotechnol. 23 (2005) 845-856
64. Assmus B., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 355 (2006) 1222-1232
65. Schachinger V., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355 (2006) 1210-1221
66. Rosenzweig A. Cardiac cell therapy - mixed results from mixed cells. N. Engl. J. Med. 355 (2006) 1274-1278
67. Ripa R.S., et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. 27 (2006) 1785-1792
68. Donovan M.J., et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127 (2000) 4531-4540
69. Rafii S., et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat. Rev. Cancer 2 (2002) 826-835
70. Herbrig K., et al. Endothelial progenitor cells in chronic renal insufficiency. Kidney Blood Press. Res. 29 (2006) 24-31
71. Walter D.H., et al. Impaired CXCR4 signalling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ. Res. 97 (2005) 1142-1151
72. Murakami M., et al. Signalling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 108 (2006) 1849-1856
73. Woodhouse E.C., et al. General mechanisms of metastasis. Cancer 80 (1997) 1529-1537
74. Yang A.D., et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res. 66 (2006) 46-51
75. Christofori G. New signals from the invasive front. Nature 441 (2006) 444-450
76. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 14 (2004) 171-179
77. Kalluri R., and Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 6 (2006) 392-401
78. Muller A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
79. Wai P.Y., and Kuo P.C. The role of osteopontin in tumor metastasis. J. Surg. Res. 121 (2004) 228-241
80. Hiratsuka S., et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2 (2002) 289-300
81. Semenza G. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
82. Wu Y., et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer 119 (2006) 1519-1529
83. Fernando N.H., and Hurwitz H.I. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin. Oncol. 30 (2003) 39-50
84. Hurwitz H., et al. Bevacizumab plus irinotecan, fluorouacil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2334-2342
85. Jubb A.M., et al. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 6 (2006) 626-635
86. Casanovas O., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
87. Miller K., et al. Can tumor angiogenesis be inhibited without resistance?. EXS 94 (2005) 95-112
88. Fidler I.J. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother. Pharmacol. 43 Suppl. (1999) S3-S10
89. Lum L.G. The new face of bispecific antibodies: targeting cancer and much more. Exp. Hematol. 34 (2006) 1-6
90. De Palma M., et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9 (2003) 789-795
91. Arafat W.O., et al. Genetically modified CD24+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clin. Cancer Res. 6 (2000) 4442-4448
92. Komarova S., et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 5 (2006) 755-766
93. Lotem J., et al. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 25 (2006) 7663-7672
94. Kalluri R., et al. Fibroblasts in cancer. Nature 6 (2006) 392-401
95. Wai P.Y., et al. The role of osteopontin in tumour metastasis. J. Surg. Res. 121 (2004) 228-241
96. Jin H., et al. A homing mechanism for bone marrow derived progenitor cell recruitment to the neovasculature. J. Clin. Invest. 116 (2006) 652-662
97. Christofori G. New signals from the invasive front. Nature 441 (2006) 444-450
98. Hiratsuka S., et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2 (2002) 289-300
99. Usui T., et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Inv. Ophth. Vis. Sci. 45 (2004) 368-373
100. Ratajczak M.Z., et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor in regulating human haemopoietic cell growth. Br. J. Haem. 103 (1998) 969-979
101. Bao S., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66 (2006) 7843-7848